Abstract: Objective To observe the clinical efficacy and security of oxaliplatin combined with capecitabine(XELOX) and oxaliplatin combined with S-1(SOX) for advanced gastric cancer(AGC)patients. Methods Fifty-two AGC patients were divided into XELOX group (25 cases) and SOX group (27 cases). For XELOX group, capecitabine 1 000 mg/m2, orally bid, days 1-14 and oxaliplatin 130 mg/m2, intravenously, day 1, 21 days was a cycle. For SOX group, S-1 40 mg/m2, orally bid, days 1-14 and oxaliplatin 130 mg/m2, intravenously, day 1, 21 days was a cycle. The dose was adjusted according to adverse effects. The efficacy was evaluated every 2 cycles. Results All patients were evaluated for efficacy and toxicity. In XELOX group, 0 patients with complete response(CR), 13 patients (52.0%) with partial response(PR), 7 patients(28.0%) with stable disease(SD), 5 patients(20.0%) with progressive disease(PD), total 13 patients (52.0%) with complete and partial response(RR). The median progression free survival was 6.9 months and the median overall survival was 12.1 months. In SOX group, 1 patient (3.7%) with CR, 12 patients (44.4%) with PR, 8 patients(29.6%) with SD, 6 patients(22.2%) with PD, total 13 patients (48.1%) with RR. The median progression free survival was 7.2 months and the median overall survival was 11.2 months. There was no significant difference of RR, PFS and OS between both groups(P>0.05). In both groups, the clinical efficacy in stage Ⅲwas significantly better than that in stage Ⅳ(P<0.01). The common toxicities included myelosuppression, anorexia, nausea, asthenia, oralmucositis, hand-foot syndrome and neurotoxicity. The incidence rate of hand-foot syndrome in XELOX group was higher than that in SOX group (P <0.01). Conclusion Both XELOX and SOX are effective for AGC patients, with tolerated toxicities.